Date Published 
April 2015

Page Count

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.


For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Kerri Kelley
Customer Service

IPR Bundle

Prenatal Diagnostic Testing - Overview


New to Insight Pharma Reports is Prenatal Diagnostics: Invasive Testing, Noninvasive Testing, and Rising Maternal Screening Methods for Preeclampsia and Preterm Labor. This report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare. Although covering standard invasive procedure, this report focuses on the noninvasive technologies either on the market or in development. 

Highlighting noninvasive methods, several companies have come out with novel technologies that allow them to analyze fetal DNA without risk of injury to the mother or fetus. Amniocentesis and chorionic villus sampling are common methods used to analyze fetal DNA for aneuploidies but at the risk of miscarriage and infection. With noninvasive procedures, screening can be done for common aneuploidies and further analysis can be done on women with only positive results. This not only decreases the amount of unnecessary invasive testing but also the amount of unnecessary stress levels of many expecting mothers. Companies participating in this section include:  

  • Sequenom 
  • Verinata Health 
  • Ariosa Diagnostics 
  • Natera 
  • Silicon Biosystems 

Other areas discussed in this report include preeclampsia and preterm labor. Preeclampsia is a common condition in women and often isn’t detected until later in pregnancy. It can lead to preterm labor, which may be fatal for both the fetus and the mother. So far, a test to screen for the likelihood of preeclampsia does not exist. Detecting the risk of preeclampsia early in pregnancy can allow the expecting mother to take necessary action to avoid preterm labor at all costs, decreasing any complications that may severely affect the fetus including death. Companies highlighted in this section include: 

  • Metabolomic Diagnostics 
  • NX PharmaGen 

Report Highlights:    

  • Company goals, customer feedback, challenges encountered, competitive advantage, platform pricing, and future endeavors
  • An exclusive Insight Pharma Reports survey specifically highlighting organizational background, areas of research, challenges encountered, and applications in development
  • Clinical trial and pipeline data on over 120 products
  • Over 130 Company Profiles
  • Exclusive interviews with:
    • Vardit Ravitsky, PhD Associate Professor, Bioethics Programs, School of Public Health, University of Montreal
    • Tom Musci, Chief Medical Officer of Ariosa Diagnostics
    • Richard Rava, Vice President, Research and Development of Verinata
    • Solomon Moshkevich, Vice-President, Marketing and Business Development of Natera
    • Robert Proulx, President & GM U.S. Operations of Silicon Biosystems
    • Charles Garvey, Chief Executive Officer of Metabolomic Diagnostics
    • Dr. Alan Ezrin and Brian Brohman, Co-Founder, Chief  Executive Officer of NX PharmaGen; Chief Business Officer of NX PharmaGen
    • William Welch; Dirk van den Boom; and Allan Bombard, President and Chief Operating Officer of Sequenom; Executive Vice President, Research & Development and Chief Technology Officer of Sequenom; Chief Medical Officer of Sequenom